Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC PatientsIlaria Grazia Zizzari, Chiara Napoletano, Hassan Rahimi et al.|Journal of Personalized Medicine|2020Cited by 44
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, <i>ERBB2</i>–Negative Metastatic Breast CancerPier Paolo Maria Berton Giachetti, Carmen Criscitiello, Stefania Morganti et al.|JAMA Network Open|2025Cited by 11